Rezolute's Ersodetug Phase 3 Interim Data Positive: 6 of 8 Patients Respond in Tumor HI Study
RZLT has more than doubled off its 52-week low of $1.07.
Summary
Rezolute announced highly positive interim results from its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism. Six out of eight enrolled participants met the primary endpoint, achieving at least a 50% reduction in intravenous glucose requirements, with all six completely discontinuing IV glucose. This follows an 8-K filed on the same date and previous positive expanded Phase 3 data for ersodetug in congenital HI (sunRIZE study) reported in May. These strong interim results significantly de-risk ersodetug for this indication and reinforce its potential as a universal treatment for hyperinsulinism. Topline results for the fully enrolled upLIFT study are expected in the second half of 2026, and the company will continue engagement with the FDA regarding the congenital HI indication.
At the time of this announcement, RZLT was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $347.6M. The 52-week trading range was $1.07 to $11.46. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.